PROMETHEUS® FIBROSpect® II is now designed to differentiate lower-stage (METAVIR F0-F2) from advanced liver fibrosis/cirrhosis (METAVIR F3-F4), which may help with hepatitis C virus treatment authorization and reimbursement.

Unique set of extracellular matrix biomarkers combined with a proprietary algorithm helps diagnose liver fibrosis using a novel index for individualized patient results.1

In a study population of chronic HCV patients (N = 696) with a fibrosis (METAVIR F3-F4) prevalence of 31.8%, PROMETHEUS FIBROSpect II sensitivity at an index of 42 was 80% and specificity was 76%. An index score of ≥42 was classified as being concordant with F3-F4 fibrosis.2
Noninvasive.
Nonfasting.
Always provides determinant test results.

• May reduce the need for liver biopsy, be used as an adjunct to biopsy, or used when biopsy is contraindicated
• Many advantages over liver biopsy:
  • No risk of indeterminant test results
  • Validated predictive algorithm is objective
  • Can be repeated frequently, easily, and safely
• No surgical costs

“An accurate assessment of fibrosis is vital in assessing the urgency for treatment...”
- AASLD-IDSA Recommendations


A Nestlé Health Science Company
Prometheus diagnostic services provide important information to aid in the diagnosis and management of certain diseases and conditions. How this information is used to guide patient care is the responsibility of the physician. Assays and methods within this test may be covered by one or more US pending or issued patents. For details, please go to www.prometheuslabs.com.